WINTON GROUP Ltd lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 169.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,550 shares of the life sciences company's stock after acquiring an additional 24,249 shares during the period. WINTON GROUP Ltd's holdings in Illumina were worth $5,151,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the business. Golden State Wealth Management LLC acquired a new stake in Illumina during the fourth quarter worth approximately $32,000. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina in the 4th quarter valued at $45,000. Assetmark Inc. raised its stake in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. purchased a new stake in Illumina in the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Price Performance
NASDAQ:ILMN traded down $2.28 during trading hours on Friday, hitting $80.00. The company's stock had a trading volume of 1,526,373 shares, compared to its average volume of 2,212,008. The business's 50-day moving average is $102.80 and its two-hundred day moving average is $126.81. The company has a market capitalization of $12.67 billion, a PE ratio of -10.42, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 52-week low of $79.30 and a 52-week high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. Royal Bank of Canada cut their target price on Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 12th. Barclays restated an "underweight" rating on shares of Illumina in a research note on Tuesday, March 11th. Canaccord Genuity Group reduced their price objective on Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Robert W. Baird lowered their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Finally, Guggenheim reduced their price target on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.
Get Our Latest Analysis on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
